Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Robert James Glynn, Sc.D., Ph.D.

Co-Author

Back to Details
This page shows the publications co-authored by Robert Glynn and Jessica Franklin.
Robert Glynn
Connection Strength
2.964
Jessica Franklin
  1. Franklin JM, Schneeweiss S, Huybrechts KF, Glynn RJ. Evaluating possible confounding by prescriber in comparative effectiveness research. Epidemiology. 2015 Mar; 26(2):238-41.
    View in: PubMed
    Score: 0.677
  2. Myers JA, Rassen JA, Gagne JJ, Huybrechts KF, Schneeweiss S, Rothman KJ, Joffe MM, Glynn RJ. Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011 Dec 01; 174(11):1213-22.
    View in: PubMed
    Score: 0.268
  3. Franklin JM, Glynn RJ, Suissa S, Schneeweiss S. Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. Clin Pharmacol Ther. 2020 Apr; 107(4):735-737.
    View in: PubMed
    Score: 0.238
  4. Franklin JM, Pawar A, Martin D, Glynn RJ, Levenson M, Temple R, Schneeweiss S. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. Clin Pharmacol Ther. 2020 Apr; 107(4):817-826.
    View in: PubMed
    Score: 0.233
  5. Yoshida K, Solomon DH, Haneuse S, Kim SC, Patorno E, Tedeschi SK, Lyu H, Franklin JM, Stürmer T, Hernández-Díaz S, Glynn RJ. Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. Am J Epidemiol. 2019 03 01; 188(3):609-616.
    View in: PubMed
    Score: 0.223
  6. Franklin JM, Glynn RJ, Martin D, Schneeweiss S. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. Clin Pharmacol Ther. 2019 04; 105(4):867-877.
    View in: PubMed
    Score: 0.223
  7. Yoshida K, Hernández-Díaz S, Solomon DH, Jackson JW, Gagne JJ, Glynn RJ, Franklin JM. Matching Weights to Simultaneously Compare Three Treatment Groups: Comparison to Three-way Matching. Epidemiology. 2017 05; 28(3):387-395.
    View in: PubMed
    Score: 0.197
  8. Schneeweiss S, Eddings W, Glynn RJ, Patorno E, Rassen J, Franklin JM. Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. Epidemiology. 2017 03; 28(2):237-248.
    View in: PubMed
    Score: 0.194
  9. Franklin JM, Eddings W, Glynn RJ, Schneeweiss S. Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. Am J Epidemiol. 2015 Oct 01; 182(7):651-9.
    View in: PubMed
    Score: 0.174
  10. Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim S, Rothman KJ, Liu J, Avorn J. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
    View in: PubMed
    Score: 0.072
  11. Kesselheim AS, Robertson CT, Myers JA, Rose SL, Gillet V, Ross KM, Glynn RJ, Joffe S, Avorn J. A randomized study of how physicians interpret research funding disclosures. N Engl J Med. 2012 Sep 20; 367(12):1119-27.
    View in: PubMed
    Score: 0.071
  12. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:69-80.
    View in: PubMed
    Score: 0.070
  13. Spoendlin J, Desai RJ, Franklin JM, Glynn RJ, Payne E, Schneeweiss S. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. Clin Pharmacol Ther. 2020 Oct; 108(4):874-884.
    View in: PubMed
    Score: 0.061
  14. Wang SV, Huybrechts KF, Fischer MA, Franklin JM, Glynn RJ, Schneeweiss S, Gagne JJ. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):383-390.
    View in: PubMed
    Score: 0.052
  15. Lauffenburger JC, Shrank WH, Bitton A, Franklin JM, Glynn RJ, Krumme AA, Matlin OS, Pezalla EJ, Spettell CM, Brill G, Choudhry NK. Association Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications: A Cohort Study. Ann Intern Med. 2017 Jan 17; 166(2):81-88.
    View in: PubMed
    Score: 0.048
  16. Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016 May 24; 353:i2607.
    View in: PubMed
    Score: 0.046
  17. Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17.
    View in: PubMed
    Score: 0.042
  18. Patrick AR, Franklin JM, Weinstein MC, Glynn RJ, Schneeweiss S. Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel. Med Decis Making. 2013 10; 33(7):949-60.
    View in: PubMed
    Score: 0.038
  19. Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S. Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013 May; 24(3):401-9.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2020 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.